adp-a2m4cd8,nivolumab
adaptimmune therapeutics,bms
['surpass', 'ovarian', 'a2m4cd8', 'adp-a2m4']
patients with relapsed/refractory ovarian cancer treated with the tcr t therapy adp-a2m4cd8 in the surpass trial had a disease control rate of 86%. #esmo22 
CGTLive™ delivers quality and relevant information to healthcare professionals on cell, gene, regenerative, and engineered medicines to ultimately improve care.